PharmaTelevision - OrthoCell: Paul Anderson explains why stem cells could be the answer for degenerated and damaged tendons

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: OrthoCell: Paul Anderson explains why stem cells could be the answer for degenerated and damaged tendons

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Paul Anderson, Managing Director of OrthoCell.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Orthocell 's Technology of tissue repair and regeneration

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Adelaide at AusBiotech's convention. On this show I have Paul Anderson, who is Managing Director of a company called Orthocell based in Perth, Western Australia. Welcome to the show.

Paul Anderson:

Thank you Fintan, happy to be here.

Fintan Walton:

Good. So Paul, interesting company based in Perth as I said you are in this whole new area of regenerative medicine could you tell us first of all about the origins of the company, where the technology comes from?

Paul Anderson:

The origins of the company really stand back to 2006 when Professor Ming Zheng from the University of Western Australia came to me and said that he had some exciting research he was doing into the growth and regeneration of human tendon tissue and at that time I felt that there was some really strong commercial indicators that we should follow this process forward.

Fintan Walton:

Okay, so obviously it's regenerative medicine what is the actual advance that's taken place, what can you do that you couldn't do before?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Paul Anderson

Managing Director

At the time of recording this PTV interview Paul Anderson works as Managing Director of Orthocell. Paul Anderson has over 14 yrs experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product and the accompanying 'grey area' interpretation, rebating pathways, marketing, sales, developing orthopedic relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd a human cell therapies company.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Orthocell

Orthocell Pty Ltd is a biotherapeutic technology development company that addresses unmet clinical needs within the orthopedics sector. The company focuses on biological therapies for tendon and ligament tissue repair and regeneration. It provides Autologous Tenocyte Implantation (ATI), a process that involves in regenerating a patient's tendon cells to assist in the treatment of torn or damaged tendons common in shoulder , ankle , and elbow injuries ; Autologous Tenocyte Therapy (ATT), which involves in regenerating a patient's own tendon cells to assist in the accelerated treatment of torn or damaged tendons, common in shoulder , ankle , and elbow injuries; and CellGro Scaffold (CellGro), which involves in the use of a novel collagen based scaffold, which acts as a delivery system for the patient's cultured tenocyte cells that are seeded into the collagen matrix and also provides biomechanical support and stabilization to the damaged tendon. The company was incorporated in 2006 and is based in Murdoch, Australia.